Target Validation Information | |||||
---|---|---|---|---|---|
Target ID | T07806 | ||||
Target Name | 5-hydroxytryptamine 1B receptor | ||||
Target Type | Successful |
||||
Drug Potency against Target | WAY-466 | Drug Info | Ki = 9.3 nM | [527381] | |
SEROTONIN | Drug Info | Ki = 18 nM | [529789] | ||
1-(7-Methoxy-naphthalen-2-yl)-piperazine | Drug Info | Ki = 2 nM | [534528] | ||
L-775606 | Drug Info | IC50 = 75 nM | [534500] | ||
Eletriptan | Drug Info | Ki = 3.14 nM | [552727] | ||
2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine | Drug Info | Ki = 32 nM | [525792] | ||
Frovatriptan | Drug Info | Ki = 2.51 nM | [528068] | ||
LY-334370 | Drug Info | Ki = 83 nM | [529496] | ||
5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole | Drug Info | Ki = 472 nM | [525845] | ||
(+/-)-nantenine | Drug Info | Ki = 100 nM | [530558] | ||
[2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine | Drug Info | Ki = 286 nM | [525845] | ||
GR-127935 | Drug Info | Ki = 0.14 nM | [527726] | ||
Almogran | Drug Info | IC50 = 12 nM | [552239] | ||
1-Naphthalen-2-yl-piperazine | Drug Info | Ki = 10.1 nM | [534528] | ||
5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole | Drug Info | Ki = 1625 nM | [525845] | ||
L-747201 | Drug Info | IC50 = 30.2 nM | [534500] | ||
5-amino-3-(N-methylpiperidin-4-yl)-1H-indole | Drug Info | Ki = 353 nM | [529496] | ||
Zolmitriptan | Drug Info | EC50 = 478 nM | [552212] | ||
Action against Disease Model | Frovatriptan | -logEC50 on isolated basilar artery: 7.86 | [553276] | Drug Info | |
References | |||||
Ref 527381 | J Med Chem. 2005 Jan 27;48(2):353-6.Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. | ||||
Ref 529789 | J Med Chem. 2008 Nov 27;51(22):7094-8.cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. | ||||
Ref 534528 | J Med Chem. 1997 Nov 21;40(24):3974-8.5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. | ||||
Ref 534500 | J Med Chem. 1997 Oct 24;40(22):3501-3.Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. | ||||
Ref 552727 | Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem. 2007;7(14):1379-93. | ||||
Ref 525792 | Bioorg Med Chem Lett. 2000 May 1;10(9):903-5.5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine. | ||||
Ref 528068 | Nat Rev Drug Discov. 2006 Mar;5(3):247-64.Adenosine receptors as therapeutic targets. | ||||
Ref 529496 | J Med Chem. 2008 Jun 26;51(12):3609-16. Epub 2008 May 29.Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide. | ||||
Ref 525845 | Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. | ||||
Ref 530558 | Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. | ||||
Ref 525845 | Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. | ||||
Ref 527726 | Bioorg Med Chem Lett. 2005 Nov 1;15(21):4786-9.Synthesis of potent and selective serotonin 5-HT1B receptor ligands. | ||||
Ref 552239 | Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol. 2000 Dec 20;410(1):33-41. | ||||
Ref 534528 | J Med Chem. 1997 Nov 21;40(24):3974-8.5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. | ||||
Ref 525845 | Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9.5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. | ||||
Ref 553276 | Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol. 1998 Aug;32(2):220-4. | ||||
Ref 534500 | J Med Chem. 1997 Oct 24;40(22):3501-3.Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. | ||||
Ref 529496 | J Med Chem. 2008 Jun 26;51(12):3609-16. Epub 2008 May 29.Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-piperidinyl)-1H-indol-5-yl]benzamide. | ||||
Ref 552212 | Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery. Br J Clin Pharmacol. 2000 Feb;49(2):126-31. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.